Eli Lilly & Co. (LLY) to Present Data for Taltz in Psoriasis at EADV

September 27, 2016 1:01 PM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Eli Lilly and Company (NYSE: LLY) will highlight clinical and patient-related health outcomes data evaluating Taltz® (ixekizumab) for the treatment of adult patients with moderate-to-severe plaque psoriasis at the annual European Academy of Dermatology and Venereology Congress (EADV), which will take place Sept. 28-Oct. 2, 2016, in Vienna, Austria.

A total of 17 abstracts, including eight oral abstracts with one late-breaker presentation, will feature sub-analyses from pivotal Phase 3 data of Taltz for the treatment of moderate-to-severe plaque psoriasis across a number of areas.

"EADV represents a tremendous opportunity for dermatologists to exchange information that helps better address unmet needs for patients," said Dr. Lotus Mallbris, Lilly's global brand development leader for Taltz. "Lilly is excited to support the evolution of new treatments in dermatology as we share new data for Taltz in the treatment of moderate-to-severe plaque psoriasis."

Studies, as well as the times and locations of each session, are highlighted below. All times are listed in Central European Time (CET).

Oral Presentations

Thursday, September 29

  • Abstract FC03.05: 13:55 – 14:05
    • Safety and Tolerability of Ixekizumab: Integrated Analysis of Safety in Patients with Moderate-to-Severe Psoriasis with More Than 7800 Patient-Years of Exposure to Ixekizumab from 7 Clinical Trials
    • Presenter: Alexandra Kimball, Massachusetts General Hospital, Boston, MA, United States
    • Location: Hall N
  • Abstract FC03.06: 14:05 – 14:15
    • Indirect Comparison of Ixekizumab and Secukinumab Using Matched-Adjusted Indirect Comparisons
    • Presenter: Alexander Schacht, Eli Lilly & Company, Indianapolis, IN, United States
    • Location: Hall N
  • Abstract FC03.08: 14:25 – 14:35
    • Efficacy and Safety of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis Plus Significant Palmoplantar Involvement: 60-Week Outcomes from UNCOVER-3
    • Presenter: Alan Menter, Baylor University Medical Center, Dallas, TX, United States
    • Location: Hall N
  • Abstract FC03.09: 14:35 – 14:45
    • Ixekizumab Treatment Enables Rapid Improvements in Health-Related Quality of Life and Itch: Results from UNCOVER-2 and UNCOVER-3
    • Presenter: Andrew Blauvelt, Oregon Medical Research Center, Portland, OR, United States
    • Location: Hall N
  • Abstract FC04.01: 15:00 – 15:10
    • Sustained Response with Ixekizumab Treatment of Scalp Psoriasis in Patients with Moderate-to-Severe Psoriasis: Results from a Phase 3 Trial (UNCOVER-3)
    • Presenter: Kristian Reich, Dermatologikum Hamburg, Hamburg, Germany
    • Location: Hall N
  • Abstract FC04.03: 15:20 – 15:30
    • Efficacy and Safety of Ixekizumab Treatment Stratified by Body Weight in Patients with Psoriasis
    • Presenter: Luis Puig, Hospital de la Santa Creu I Sant Pau, Dermatology, Barcelona, Spain
    • Location: Hall N

Saturday, October 1

  • Late-Breaking Abstract D3T01.1K: 16:10 – 16:20
    • Efficacy and Safety of Ixekizumab Compared to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized Head-to-Head Trial
    • Presenter: Kristian Reich, Dermtologikum Hamburg, Hamburg, Germany
    • Location: Hall A
  • Abstract FC08.08: 16:10 - 16:20
    • Ixekizumab Treatment is Associated with Early Clearance of Facial Psoriasis and Subsequent Overall Plaque Clearance
    • Presenter: Lyn Guenther, University of Western Ontario, London, ON, Canada
    • Location: Hall N

e-Poster Presentations

Wednesday, September 28 – Sunday, October 2Location/Time: Hall N, 13:25 – 14:45

  • Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions in Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab Compared with Placebo or Etanercept from Three Phase 3 Trials
  • Continued Treatment with Ixekizumab Maintained Long-Term Improvements in Itch: Results from UNCOVER-3
  • Relationship of Itch and Psoriasis Area and Severity Index Improvement in Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab or Etanercept
  • Impact of Ixekizumab Treatment Withdrawal on Skin Symptoms in Responder Patients: Results from UNCOVER-1 and UNCOVER-2, Two Randomized Phase 3 Trials
  • Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis: A Subanalysis of UNCOVER-3
  • Efficacy and Safety of Ixekizumab in Patients Previously Treated with Etanercept
  • Efficacy and Safety of Ixekizumab in Patients with Plaque Psoriasis Across Different Degrees of Disease Severity (Results from UNCOVER-2 and UNCOVER-3)
  • Ixekizumab Allows Patients to Maintain Relationship Improvements over 60 Weeks: Integrated Results from UNCOVER-1 and -2
  • Using the Absolute Psoriasis Area and Severity Index for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis

Indications and UsageTaltz® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA, Management Comments

Add Your Comment